MedTrace Logo

Virtual Reality Cognitive Stimulation for Alzheimer's

NCT07645638 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-06-12

No results posted yet for this study

Summary

This study aims to evaluate whether immersive virtual reality (VR) can improve cognitive function and memory in patients with Alzheimer's disease. Twenty participants in Burgos, Spain, will engage in VR sessions that recreate scenes from 1960s Burgos, representing environments familiar from the participants' youth. The effects of these VR-based cognitive stimulation sessions will be assessed through pre- and post-intervention evaluations, including behavioral observations, EEG monitoring of brain activity, and standardized neurocognitive tests (Montreal Cognitive Assessment, Clock-Drawing Test, and Verbal Fluency Test).

Conditions

Interventions

OTHER

Virtual reality

The intervention consists of a series of immersive virtual reality (VR) sessions designed to provide cognitive stimulation for patients diagnosed with Alzheimer's disease. Participants in the experimental group will be exposed to VR environments that recreate the city of Burgos as it appeared in the 1960s, an era corresponding to their youth. These VR experiences will include familiar scenes, landmarks, and culturally relevant settings designed to evoke personal memories and enhance cognitive engagement.

Sponsors & Collaborators

  • Universidad de Burgos

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-08
Primary Completion
2025-03-20
Completion
2025-03-20

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07645638 on ClinicalTrials.gov